Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Candel Therapeutics (CADL) Income towards Parent Company (2020 - 2025)

Candel Therapeutics' Income towards Parent Company history spans 4 years, with the latest figure at -$10.6 million for Q4 2023.

  • On a quarterly basis, Income towards Parent Company fell 34.3% to -$10.6 million in Q4 2023 year-over-year; TTM through Dec 2023 was -$38.9 million, a 10.49% decrease, with the full-year FY2025 number at -$46.5 million, down 35.19% from a year prior.
  • Income towards Parent Company hit -$10.6 million in Q4 2023 for Candel Therapeutics, down from -$9.0 million in the prior quarter.
  • Over the last five years, Income towards Parent Company for CADL hit a ceiling of -$2.5 million in Q2 2020 and a floor of -$10.6 million in Q4 2023.
  • Historically, Income towards Parent Company has averaged -$7.4 million across 4 years, with a median of -$8.0 million in 2021.
  • Biggest five-year swings in Income towards Parent Company: tumbled 197.01% in 2021 and later rose 0.32% in 2023.
  • Tracing CADL's Income towards Parent Company over 4 years: stood at -$6.1 million in 2020, then fell by 27.57% to -$7.8 million in 2021, then decreased by 1.6% to -$7.9 million in 2022, then crashed by 34.3% to -$10.6 million in 2023.
  • Business Quant data shows Income towards Parent Company for CADL at -$10.6 million in Q4 2023, -$9.0 million in Q3 2023, and -$9.8 million in Q2 2023.